What question did this study set out to answer?

The research aims to evaluate how dapagliflozin affects arterial stiffness in CKD patients, regardless of diabetes status and blood pressure control.

January 10, 2026High Blood Pressure & Cardiovascular Prevention0 citationsOpen Access

Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial

ERElisa Russo FCFrancesca Cappadona LMLucia Macciò

Key Points

The research aims to evaluate how dapagliflozin affects arterial stiffness in CKD patients, regardless of diabetes status and blood pressure control.
Observational analysis from the GLUTREPRO trial

Structured PICO

Does dapagliflozin improve ambulatory arterial stiffness index (AASI) and 24h-BP behavior in patients with albuminuric CKD?

Population

32 patients with albuminuric CKD (eGFR 25-75 ml/min/1.73m2) with or without type 2 diabetes, mean age 58, 91% male. Key inclusion: at least 4 weeks of therapy with metformin and/or repaglinide (if diabetic), optimized standard therapy.

Intervention

Dapagliflozin 10 mg oral once daily added to optimized standard therapy for 6 months (randomized phase) followed by 12 months open-label.

Comparator

Matching placebo added to optimized standard therapy for 6 months.

Outcome

24h-BP behavior and ambulatory arterial stiffness index (AASI) at 6 months (pre-defined secondary outcome of the GLUTREPRO trial)surrogate

Dapagliflozin reduces arterial stiffness in patients with albuminuric CKD independently of blood pressure lowering, suggesting direct favorable vascular remodeling effects.

Abstract

Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) confer cardiovascular and renal protection, but their impact on blood pressure (BP) and vascular stiffness in chronic kidney disease (CKD) is not fully defined. Aim To investigate the effect of dapagliflozin on 24h-BP behavior and ambulatory arterial stiffness index (AASI) as a predefined secondary outcome of the GLUTREPRO trial.

Ask AI

Helpful

Bookmark

View Full Paper